PCL patients should be considered primary beneficiaries for the newer novel agents, alone or in combination, such as second-generation proteasome inhibitors (Carfilzomib, Ixazomib), third-generation immunomodulatory drugs (Pomalidomide), and monoclonal antibodies (Elotuzumab, Daratumumab), as well as inhibitors of histone deacetylase, Akt, or mTOR [3,62,63,64,65]. This evidence concerns the gene MTOR and plasma cell leukemia.